The aim of this study was to evaluate the potential effects of isomaltodextrin (IMD), a dietary saccharide polymer derived from enzymatically produced from starch, on the ability to alter immune response (IR) bias to hen egg ovalbumin (Ova) induced allergic inflammation in mice. Groups of Balb/c mice were pre-treated with various doses of IMD in drinking water (1.0, 2.5, and 5.0% w/v) for 6 weeks and subsequently sensitized to the Ova together with continuous administration of IMD. To evaluate changes in immune response bias, immunoglobulin isotype-associated antibody activity, concentrations of type 1 and 2 cytokines and the percentage of T-regulatory cells (T-regs) in blood were measured. Clinical signs of allergy were assessed after oral challenge with Ova. Treatment with IMD did not significantly alter the frequency of clinical signs, however there was a trend in the overall reduction of clinical signs. Effect on IR bias was observed in the treatment groups as reflected by reduction in a type 1-biased phenotype as evident by decrease in isotype-specific IgE, IgG and increase in IL-12 cytokine production and a high proportion of T-regs. This study revealed that IMD could be a useful prophylactic candidate for alteration of allergic IR bias in mice and an immune-stimulator for reducing egg induced allergic reactions.

本研究的目的是评估异麦芽糊精 (IMD) 的潜在影响，异麦芽糊精 (IMD) 是一种膳食糖类聚合物，由淀粉酶促产生，能够改变鸡蛋卵白蛋白 (Ova) 引起的过敏性炎症的免疫反应 (IR) 偏差。老鼠。 Balb/c 小鼠组用饮用水中的不同剂量的 IMD（1.0、2.5 和 5.0% w/v）预处理 6 周，随后持续给予 IMD，使卵子致敏。为了评估免疫反应偏差的变化，测量了免疫球蛋白同种型相关抗体活性、1 型和 2 型细胞因子的浓度以及血液中 T 调节细胞 (T-reg) 的百分比。口服 Ova 后评估过敏的临床症状。 IMD 治疗并没有显着改变临床症状的频率，但临床症状总体上有减少的趋势。在治疗组中观察到对 IR 偏倚的影响，表现为 1 型偏向表型的减少，这通过同种型特异性 IgE、IgG 的减少以及 IL-12 细胞因子产生的增加和 T-reg 的高比例来明显体现。这项研究表明，IMD 可能是改变小鼠过敏性 IR 偏差的有用预防候选药物，也是减少鸡蛋引起的过敏反应的免疫刺激剂。